NATICK, Mass. and VANCOUVER, B.C., Nov. 8 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE:BSX) and Angiotech Pharmaceuticals, Inc. (Nasdaq: ANPI; TSX: ANP) announced today that they have jointly received the Canadian American Business Council (CABC) 2005 Achievement Award, which recognizes innovative and successful alliances between Canadian and American firms. The award was presented today at the Council's 11th annual business achievement awards ceremony and policy forum held in Calgary, Alberta, Canada. The CABC Achievement Award is given each year to two companies whose cross-border joint enterprise has demonstrated strong business growth, remarkable innovation, and the capacity to provide the allies with a global advantage. The winners are chosen by an international panel of judges using standards that examine sustained profitability, job creation, financial strength, environmental responsibility, corporate synergy, exceptional imagination and remarkable innovation. "We are very pleased that our alliance with Angiotech has been recognized by the CABC," said Jim Tobin, President and Chief Executive Officer of Boston Scientific. "The innovative combination of our TAXUS(R) stent technology with Angiotech's paclitaxel drug technology has resulted in the world's most successful drug-eluting coronary stent system. The 1.8 million stents implanted to date in patients worldwide is a testament to the strength of the alliance, and to the employees at Boston Scientific and Angiotech who made this revolutionary technology possible." "This award is a tribute to the hard work and dedication of employees at both companies," said William Hunter, Chief Executive Officer of Angiotech. "The complexity of the joint project was enormous but we were able to marry our separate pharmaceutical and device technologies to deliver an innovative combination product for the global market." Executives from Boston Scientific and Angiotech also participated in a policy forum and panel discussion titled "The Cross Border Security and Prosperity Partnership". About The Canadian American Business Council The Canadian American Business Council is the premier voice of the Canadian-American business community and is headquartered in Washington, D.C. Established in 1987, the Council is a non-profit, issues-oriented organization dedicated to elevating the private sector perspective on issues that affect Canada and the United States. For more information, please visit http://www.canambusco.org/. About Angiotech Pharmaceuticals Vancouver-based Angiotech Pharmaceuticals, Inc., a specialty pharmaceutical company focusing on drug-coated medical devices and biomaterials, is dedicated to enhancing the performance of medical devices and biomaterials through the innovative uses of pharma-therapeutics. To find out more about Angiotech Pharmaceuticals, Inc. (Nasdaq: ANPI; TSX: ANP), please visit our website at http://www.angiotech.com/. About Boston Scientific Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: http://www.bostonscientific.com/. This press release contains forward-looking statements. Boston Scientific wishes to caution the reader of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, risks associated with new product development and commercialization, clinical trials, intellectual property, regulatory approvals, competitive offerings, Boston Scientific's overall business strategy, and other factors described in Boston Scientific's filings with the Securities and Exchange Commission. CONTACT: Boston Scientific Angiotech Pharmaceuticals Milan Kofol Todd Young 508-650-8569 604-221-7676 ext 6933 Investor Relations VP Investor Relations & Communications Boston Scientific Corporation Angiotech Pharmaceuticals, Inc. Paul Donovan Rui Avelar 508-650-8541 604-221-7676 ext 6996 Media Relations Sr. VP Medical Affairs & Communications Boston Scientific Corporation Angiotech Pharmaceuticals, Inc. Wendy Carhart 503-443-7354 Media Relations Waggener Edstrom Bioscience DATASOURCE: Boston Scientific Corporation CONTACT: Milan Kofol, Investor Relations, +1-508-650-8569, Paul Donovan, Media Relations, +1-508-650-8541, both of Boston Scientific; or Todd Young, VP Investor Relations & Communications, +1-604-221-7676, ext. 6933, or Rui Avelar, Sr. VP Medical Affairs & Communications, +1-604-221-7676, ext. 6996, both of Angiotech Pharmaceuticals, Inc.; or Wendy Carhart, Media Relations of Waggener Edstrom Bioscience, +1-503-443-7354 Web site: http://www.bostonscientific.com/ http://www.angiotech.com/ http://www.canambusco.org/

Copyright